• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Leukoreduction of Platelet Units Followed by Mirasol Pathogen Reduction May Prevent Alloimmunization

August 30, 2017

Alloimmunization to donor platelets is common in transfused, immunosuppressed oncology patients. Leukoreduction reduces alloimmunization by more than half. Researchers recently investigated different methods to further reduce alloimmunization after platelet transfusion including leukoreduction with different filters, γ-irradation and Mirasol pathogen reduction using a dog transfusion model. Using a highly immunogenic model, most donor/recipient dog pairs were antigen incompatible (88%), and transfusions occurred weekly for up to 8 weeks or until platelet refractoriness occurred. Almost half of the dogs transfused (6/13, 4%) with leukoreduced platelets did not develop platelet refractoriness. Neither γ-irradiation nor Mirasol pathogen reduction alone prevented alloimmune platelet refractoriness. γ-irradation in combination with other methods also was not successful. However, leuko filtration of donor platelets followed by Mirasol pathogen reduction was successful in preventing alloimmune platelet refractoriness in 31/32 (97%) of dog recipients, and recipients did not develop antibodies to donor white blood cells. Mirasol pathogen reduction of platelets is approved in Europe and is awaiting approval in the United States. This approach deserves further study, especially in immunocompetent patients.

Reference:

1. Slichter SJ, Pellham E, Bailey SL, Christoffel T, Gettinger I, Gaur L, Latchman Y, Nelson K, Bolgiano D. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. Blood 2017;130 (8); 1052-1060.

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • ABO Blood Group Associated with COVID-19 Severity

  • FDA Approves Blood Tracking Device

  • Aspirin Increases Bleeding Risk

Show Comments

Reader Interactions

Comments

  1. Reuben says

    September 6, 2017 at 2:53 pm

    Have a feeling this will be a big problem in our situation in Kenya as no leukoreduction in platelets transfusion.

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley